Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
About this trial
This is an interventional treatment trial for Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed newly diagnosed Hodgkin lymphoma (HL) meeting one of the following criteria:
- Classical disease
- Nodular lymphocyte-predominant disease
Stage III or IV disease with B symptoms, as defined by ≥ 1 of the following:
- Unexplained weight loss > 10% within the past 6 months
- Unexplained recurrent fever > 38°C within the past month
- Recurrent drenching night sweats within the past month
Creatinine clearance or radioisotope GFR ≥ 70 mL/min OR maximum serum creatinine based on age/gender as follows:
- 0.4 mg/dL (1 to 5 months)
- 0.5 mg/dL (6 to 11 months)
- 0.6 mg/dL (12 to 23 months)
- 0.8 mg/dL (2 to 5 years)
- 1 mg/dL (6 to 9 years)
- 1.2 mg/dL (10 to 12 years)
- 1.5 mg/dL (males) or 1.4 mg/dL (females) (13 to 15 years)
- 1.7 mg/dL (males) or 1.4 mg/dL (females) (≥ 16 years)
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN) for age
- AST or ALT < 2.5 times ULN for age
- Shortening fraction ≥ 27% by ECHO OR ejection fraction ≥ 50% by MUGA (unless due to large mediastinal mass from HL)
FEV_1/FVC > 60% by pulmonary function tests (PFT) (unless due to large mediastinal mass fromHL)
For children who are unable to cooperate for PFTs, the criteria are:
- No evidence of dyspnea at rest
- No exercise intolerance
- Pulse oximetry > 92% on room air
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No pathologic prolongation of QTc interval (> 450 milliseconds) on 12-lead ECG
- No prior chemotherapy, biological response modifiers (e.g., monoclonal antibody therapy), or radiotherapy
- At least 28 days since prior corticosteroids except for emergent treatment for respiratory distress or spinal cord compression, or for treatment of allergy to contrast agent required for CT scan
No other concurrent cancer chemotherapy or immunomodulating agents (including steroids)
- Concurrent corticosteroid therapy as treatment or prophylaxis for anaphylactic reactions allowed
- No concurrent pegfilgrastim
Sites / Locations
- Children's Hospital of Alabama
- University of Alabama at Birmingham
- University of South Alabama
- Phoenix Childrens Hospital
- Arkansas Children's Hospital
- University of Arkansas for Medical Sciences
- Southern California Permanente Medical Group
- City of Hope Medical Center
- Loma Linda University Medical Center
- Miller Children's Hospital
- Children's Hospital Los Angeles
- Children's Hospital Central California
- Children's Hospital and Research Center at Oakland
- Kaiser Permanente-Oakland
- Childrens Hospital of Orange County
- University of California at Davis Cancer Center
- Rady Children's Hospital - San Diego
- University of California San Francisco Medical Center-Parnassus
- Santa Barbara Cottage Hospital
- Children's Hospital Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
- Connecticut Children's Medical Center
- Yale University
- Alfred I duPont Hospital for Children
- Children's National Medical Center
- Lombardi Comprehensive Cancer Center at Georgetown University
- Lee Memorial Health System
- Memorial Healthcare System - Joe DiMaggio Children's Hospital
- Nemours Children's Clinic - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center
- Miami Children's Hospital
- Baptist Hospital of Miami
- Florida Hospital
- Nemours Children's Clinic - Orlando
- UF Cancer Center at Orlando Health
- Nemours Children's Clinic - Pensacola
- All Children's Hospital
- Saint Joseph Children's Hospital of Tampa
- Saint Mary's Hospital
- Children's Healthcare of Atlanta - Egleston
- Georgia Regents University
- University of Hawaii
- Saint Luke's Mountain States Tumor Institute
- Lurie Children's Hospital-Chicago
- University of Illinois
- University of Chicago
- Advocate Children's Hospital-Oak Lawn
- Advocate Lutheran General Hospital.
- Saint Jude Midwest Affiliate
- Indiana University Medical Center
- Riley Hospital for Children
- Saint Vincent Hospital and Health Services
- Blank Children's Hospital
- University of Iowa Hospitals and Clinics
- University of Kentucky
- Kosair Children's Hospital
- Tulane University Health Sciences Center
- Children's Hospital-Main Campus
- University of Maryland/Greenebaum Cancer Center
- Sinai Hospital of Baltimore
- Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center
- Walter Reed National Military Medical Center
- Baystate Medical Center
- C S Mott Children's Hospital
- Wayne State University/Karmanos Cancer Institute
- Saint John Hospital and Medical Center
- Michigan State University Clinical Center
- Helen DeVos Children's Hospital at Spectrum Health
- Bronson Methodist Hospital
- Kalamazoo Center for Medical Studies
- Children's Hospitals and Clinics of Minnesota - Minneapolis
- University of Minnesota Medical Center-Fairview
- Mayo Clinic
- University of Mississippi Medical Center
- Columbia Regional
- University of Missouri - Ellis Fischel
- The Childrens Mercy Hospital
- Washington University School of Medicine
- Children's Hospital and Medical Center of Omaha
- University of Nebraska Medical Center
- Nevada Cancer Research Foundation CCOP
- Dartmouth Hitchcock Medical Center
- Hackensack University Medical Center
- UMDNJ - Robert Wood Johnson University Hospital
- Newark Beth Israel Medical Center
- Saint Joseph's Regional Medical Center
- Overlook Hospital
- University of New Mexico Cancer Center
- University of New Mexico
- Montefiore Medical Center - Moses Campus
- Roswell Park Cancer Institute
- Winthrop University Hospital
- The Steven and Alexandra Cohen Children's Medical Center of New York
- Columbia University Medical Center
- Memorial Sloan-Kettering Cancer Center
- Weill Medical College of Cornell University
- University of Rochester
- State University of New York Upstate Medical University
- New York Medical College
- Mission Hospital-Memorial Campus
- University of North Carolina
- Carolinas Medical Center
- Novant Health Presbyterian Medical Center
- Duke University Medical Center
- Wake Forest University Health Sciences
- Sanford Medical Center-Fargo
- Children's Hospital Medical Center of Akron
- Cincinnati Children's Hospital Medical Center
- Rainbow Babies and Childrens Hospital
- Cleveland Clinic Foundation
- Nationwide Children's Hospital
- Dayton Children's Hospital
- The Toledo Hospital/Toledo Children's Hospital
- University of Oklahoma Health Sciences Center
- Legacy Emanuel Hospital and Health Center
- Oregon Health and Science University
- Lehigh Valley Hospital - Muhlenberg
- Geisinger Medical Center
- Penn State Hershey Children's Hospital
- Children's Hospital of Philadelphia
- Children's Oncology Group
- Saint Christopher's Hospital for Children
- Children's Hospital of Pittsburgh of UPMC
- Rhode Island Hospital
- Medical University of South Carolina
- Palmetto Health Richland
- BI-LO Charities Children's Cancer Center
- Greenville Cancer Treatment Center
- Sanford USD Medical Center - Sioux Falls
- T C Thompson Children's Hospital
- East Tennessee Childrens Hospital
- Vanderbilt-Ingram Cancer Center
- Dell Children's Medical Center of Central Texas
- Driscoll Children's Hospital
- Medical City Dallas Hospital
- University of Texas Southwestern Medical Center
- Brooke Army Medical Center
- Cook Children's Medical Center
- Baylor College of Medicine
- Covenant Children's Hospital
- Methodist Children's Hospital of South Texas
- University of Texas Health Science Center at San Antonio
- Scott and White Memorial Hospital
- University of Vermont
- Inova Fairfax Hospital
- Childrens Hospital-King's Daughters
- Virginia Commonwealth University
- Seattle Children's Hospital
- Providence Sacred Heart Medical Center and Children's Hospital
- Mary Bridge Children's Hospital and Health Center
- Madigan Army Medical Center
- West Virginia University Charleston
- Saint Vincent Hospital
- University of Wisconsin Hospital and Clinics
- Marshfield Clinic
- Midwest Children's Cancer Center
- Sydney Children's Hospital
- Royal Brisbane and Women's Hospital
- Women's and Children's Hospital-Adelaide
- Royal Children's Hospital
- Princess Margaret Hospital for Children
- Alberta Children's Hospital
- University of Alberta Hospital
- British Columbia Children's Hospital
- CancerCare Manitoba
- IWK Health Centre
- Cancer Centre of Southeastern Ontario at Kingston General Hospital
- Children's Hospital of Eastern Ontario
- Hospital for Sick Children
- The Montreal Children's Hospital of the MUHC
- Centre Hospitalier Universitaire Sainte-Justine
- Centre Hospitalier Universitaire de Quebec
- Allan Blair Cancer Centre
- Saskatoon Cancer Centre
- Schneider Children's Medical Center of Israel
- Chaim Sheba Medical Center
- San Jorge Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Regimen I (consolidation therapy)
Regimen II (consolidation therapy)
Induction: all patient
Patients receive 2 more courses of ABVE-PC comprising doxorubicin hydrochloride IV over 1-120 minutes and cyclophosphamide IV over 30-60 minutes on days 1 and 2; bleomycin sulfate IV over at least 10 minutes or subcutaneously (SC) and vincristine sulfate IV on days 1 and 8; etoposide IV over 1-2 hours on days 1-3; oral prednisone twice daily on days 1-7; and filgrastim SC or IV daily beginning on day 4 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression.
Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
All patients receive ABVE-PC induction therapy then they are assigned to Group 2 (RER), Group 3 (SER) or taken off study if they develop progressive disease.